For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Avanos Medical Inc’s stock clocked out at $11.25, up 0.45% from its previous closing price of $11.2. In other words, the price has increased by $0.45 from its previous closing price. On the day, 0.65 million shares were traded. AVNS stock price reached its highest trading level at $11.63 during the session, while it also had its lowest trading level at $11.18.
Ratios:
To gain a deeper understanding of AVNS’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.78 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.94. For the most recent quarter (mrq), Quick Ratio is recorded 1.58 and its Current Ratio is at 2.64. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.15.
On May 22, 2023, CL King started tracking the stock assigning a Buy rating and target price of $31.
Stephens Downgraded its Overweight to Equal-Weight on August 04, 2021, whereas the target price for the stock was revised from $60 to $45.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 13 ’25 when BLACKFORD GARY bought 40,000 shares for $10.99 per share. The transaction valued at 439,800 led to the insider holds 40,000 shares of the business.
BLACKFORD GARY bought 20,000 shares of AVNS for $219,500 on Aug 13 ’25. The Director now owns 91,593 shares after completing the transaction at $10.97 per share. On Mar 06 ’25, another insider, Holbrook Kerr, who serves as the SVP, Chief Commercial Officer of the company, sold 7,000 shares for $15.25 each. As a result, the insider received 106,778 and left with 82,047 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVNS now has a Market Capitalization of 522028128 and an Enterprise Value of 569027904. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.75 while its Price-to-Book (P/B) ratio in mrq is 0.67. Its current Enterprise Value per Revenue stands at 0.822 whereas that against EBITDA is 6.444.
Stock Price History:
The Beta on a monthly basis for AVNS is 1.11, which has changed by -0.5134083 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, AVNS has reached a high of $25.36, while it has fallen to a 52-week low of $9.30. The 50-Day Moving Average of the stock is -4.30%, while the 200-Day Moving Average is calculated to be -22.91%.
Shares Statistics:
It appears that AVNS traded 546.31K shares on average per day over the past three months and 1121810 shares per day over the past ten days. A total of 46.31M shares are outstanding, with a floating share count of 44.91M. Insiders hold about 3.21% of the company’s shares, while institutions hold 96.87% stake in the company. Shares short for AVNS as of 1753920000 were 1902726 with a Short Ratio of 3.48, compared to 1751241600 on 1457215. Therefore, it implies a Short% of Shares Outstanding of 1902726 and a Short% of Float of 5.81.
Earnings Estimates
The performance of Avanos Medical Inc (AVNS) in the stock market is under the watchful eye of 1.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.25, with high estimates of $0.25 and low estimates of $0.25.
Analysts are recommending an EPS of between $0.8 and $0.8 for the fiscal current year, implying an average EPS of $0.8. EPS for the following year is $0.9, with 1.0 analysts recommending between $0.9 and $0.9.
Revenue Estimates
In the current quarter, 1 analysts expect revenue to total $164.5M. It ranges from a high estimate of $164.5M to a low estimate of $164.5M. As of the current estimate, Avanos Medical Inc’s year-ago sales were $170.4MFor the next quarter, 1 analysts are estimating revenue of $169M. There is a high estimate of $169M for the next quarter, whereas the lowest estimate is $169M.
A total of 1 analysts have provided revenue estimates for AVNS’s current fiscal year. The highest revenue estimate was $676M, while the lowest revenue estimate was $676M, resulting in an average revenue estimate of $676M. In the same quarter a year ago, actual revenue was $687.8MBased on 1 analysts’ estimates, the company’s revenue will be $685M in the next fiscal year. The high estimate is $685M and the low estimate is $685M.
